Over the past decade, protein-based therapeutics have emerged as a key driver of growth in the pharmaceutical industry. R&D pipelines have filled with biologics and monoclonal antibodies have become the best-selling drugs around the world. Despite the success of this segment, the size and complexity of protein molecules create specific challenges when developing these types of therapeutics.